Keyuan Pharma, a company under Linuo Group, announces its successful initial public offering (IPO) on the Innovative Enterprise Board of Shenzhen Stock Exchange. The company's shares began trading under the ticker symbol 301281 on April 4, 2023.
The company has been focusing on the R&D and manufacturing of chemical APIs since its establishment in 2004 and is now expanding its business to chemical preparations based on its products. After nearly 20 years of development, Keyuan Pharma has reached a strong production capacity. Supported by modern synthesis facilities, mature synthesis routes and GMP-compliant QC standards, it can now reach higher reaction yield and product purity with lower wastes and emissions.
The funds raised shall be mainly invested in technology transformation of an integrated API production line, an eco-friendly flexible API production line, construction of a research institute and drug R&D projects.